- Roche’s enicepatide shows dose-dependent blood sugar and weight loss in Phase 2 diabetes trialRoche reported that its injectable GLP-1/GIP dual agonist enicepatide, acquired through the Carmot Therapeutics purchase, achieved reductions in blood glucose and body weight in a Phase 2 study of…
- Siemens Healthineers partners with Novo to raise awareness and testing for fatty liver diseaseSiemens Healthineers and Novo have announced a collaboration aimed at increasing awareness and improving diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) and its progre…